
Nascent Biotech, Inc.
OTC:NBIO
Overview | Financials
Company Name | Nascent Biotech, Inc. |
Symbol | NBIO |
Currency | USD |
Price | 0.2 |
Market Cap | 29,927,398 |
Dividend Yield | 0% |
52-week-range | 0.032 - 0.43 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Sean Carrick |
Website | https://www.nascentbiotech.com |
An error occurred while fetching data.
About Nascent Biotech, Inc.
Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD